Technical Note: Developing a melanocortin pipeline
CLINUVEL today announced an update on its commercial development of the analogue...
Read MoreNEURACTHEL® manufacturing processes advance
CLINUVEL today announced an update on its commercial development of the analogue...
Read MoreCLINUVEL Communiqué VI
Melbourne, Australia, 23 December 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read MoreJefferies London Healthcare Conference
CLINUVEL's Chief Executive Officer, Dr Philippe Wolgen, presents to the Jefferies Healthcare...
Read MoreCLINUVEL Communiqué V
News Communiqué V discusses CLINUVEL's strong financial results in the face of...
Read MoreResults of Annual General Meeting 2022
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read MoreCLINUVEL Pharmaceuticals Investor Briefing Melbourne
CLINUVEL held an Investor Briefing in Melbourne, with a presentation by Managing...
Read MoreCLINUVEL PHARMACEUTICALS LTD Annual General Meeting - Notice of Meeting & Explanatory Memorandum 2022
CLINUVEL released the formal Notice of Meeting and Explanatory Memorandum for its...
Read MoreStrategic Update V
CLINUVEL today announced its fifth Strategic Update, focused on the evolution and...
Read MoreH.C. Wainwright 24th Annual Global Investment Conference
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read MoreCLINUVEL Kommuniqué IV
Seit dem letzten News Communiqué vom 23. Juni hat CLINUVEL die Entwicklung...
Read More